Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Université de Montréal
$105,000.00
Examining the impact of contacts with healthcare and harm-reduction services on the injection trajectories of people who inject drugs
FY 2015-16
Summary
People who inject drugs (PWID) are at high risk of infection with hepatitis C virus (HCV) and human immunodeficiency virus (HCV). Previous research has suggested that the injection patterns of these individuals evolve differently over time, with some injecting persistently at high, moderate and low frequency and others having patterns of injection that are changing (decreasing, fluctuating). Yet, it is unclear whether PWID who have specific trajectories of injection are more likely to become infected with HIV or HCV than others. In addition, whether contacts with healthcare and harm reduction services can lead to subsequent decreases in PWID's courses of injection has not been previously examined. Using over 20-years of data collected from a community-based study of PWID in Montreal (1992- ), our study has three aims: 1) to examine whether there are sub-groups of PWID who have distinct courses of injection frequency over time, 2) to compare the risk of HIV and HCV infection among sub-groups, and 3) to examine whether contacts with healthcare and harm reduction services can lead to subsequent decreases in injection frequency within each sub-group. To be eligible for enrollment in the study, PWID must have injected drugs in the previous 6 months. At each semi-annual interview, they provide blood for HIV/HCV testing and information on their socio-demographic characteristics, injection drug use patterns (including their frequency of daily injection in the previous month and past 6 months), and contacts with healthcare (primary, addiction and psychiatric) and harm reduction (needle exchange programs) services in the previous 6 months. A total of 4235 PWID have been enrolled in the study (3078 and 2549 completed 2 and 3 visits, respectively), and will be available for the analyses. Our findings have the potential to inform the development of HIV and HCV prevention strategies tailored to the individual injection trajectories of PWID.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
347963
Name
Artenie Andreea A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
Examining the impact of contacts with healthcare and harm-reduction services on the injection trajectories of people who inject drugs
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Addiction; Epidemiology; Growth Mixture Modelling; Hepatitis C Virus; Hiv; Injection Drug Use; Trajectory
Abstract
People who inject drugs (PWID) are at high risk of infection with hepatitis C virus (HCV) and human immunodeficiency virus (HCV). Previous research has suggested that the injection patterns of these individuals evolve differently over time, with some injecting persistently at high, moderate and low frequency and others having patterns of injection that are changing (decreasing, fluctuating). Yet, it is unclear whether PWID who have specific trajectories of injection are more likely to become infected with HIV or HCV than others. In addition, whether contacts with healthcare and harm reduction services can lead to subsequent decreases in PWID's courses of injection has not been previously examined. Using over 20-years of data collected from a community-based study of PWID in Montreal (1992- ), our study has three aims: 1) to examine whether there are sub-groups of PWID who have distinct courses of injection frequency over time, 2) to compare the risk of HIV and HCV infection among sub-groups, and 3) to examine whether contacts with healthcare and harm reduction services can lead to subsequent decreases in injection frequency within each sub-group. To be eligible for enrollment in the study, PWID must have injected drugs in the previous 6 months. At each semi-annual interview, they provide blood for HIV/HCV testing and information on their socio-demographic characteristics, injection drug use patterns (including their frequency of daily injection in the previous month and past 6 months), and contacts with healthcare (primary, addiction and psychiatric) and harm reduction (needle exchange programs) services in the previous 6 months. A total of 4235 PWID have been enrolled in the study (3078 and 2549 completed 2 and 3 visits, respectively), and will be available for the analyses. Our findings have the potential to inform the development of HIV and HCV prevention strategies tailored to the individual injection trajectories of PWID.
Competitiondate
201510
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Artenie, Andreea A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~